drugset
drugset / Trial / NCT04876924

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

NCT04876924 ↗

Phase 1 Completed 92 enrolled Cantero Therapeutics, a BridgeBio company Celerion · collab
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of BBP-711 in healthy adult volunteers.

Timeline

Start
2021-04-29
Primary completion
2022-02-27
Completion
2022-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BBP-711 Unknown — Oral

Indications

No indication recorded.